Comparative study between docetaxel, oxaliplatin plus S-1 and DCF regimen as first-line therapy in patients with advanced gastric cancer

Chinese Journal of Cancer Prevention and Treatment

Volumn 22, Issue 2, 2015, Pages 134-137

  Chen, Jing Hua ^a   Shen, Wei Xi ^a   Xia, Jun Xian ^a   Xu, Rui Lian ^a   Zhu, Mei Qin ^a   Xu, Min ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Advanced gastric cancer; Docetaxel; First line therapy; Oxaliplatin; S 1

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN;

ADVANCED CANCER; ADVANCED GASTRIC CANCER; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; TREATMENT RESPONSE;

EID: 84922670497     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Lee JH, Kim SH, Oh SY, et al. Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer[J]. Korean J Intern Med, 2013, 28(3): 314-321.
2. Luo H, Yu Z, Gao H, et al. Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer[J]. J BUON, 2013, 18(1): 154-161.
3. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group[J]. J Clin Oncol, 2007, 25(22): 3205-3209.
4. Kanat O, O'Neil BH. Metastatic gastric cancer treatment: a little slow but worthy progress[J]. Med Oncol, 2013, 30(1): 464.
5. Huang D, Ba Y, Xiong J, et al. A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer[J]. Eur J Cancer, 2013, 49(14): 2995-3002.
6. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group[J]. J Clin Oncol, 2006, 24(31): 4991-4997.
7. Kim YS, Sym SJ, Park SH, et al. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer[J]. Cancer Chemother Pharmacol, 2014, 73(1): 163-169.
8. Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis[J]. Gastric Cancer, 2011, 14(1): 50-55.
9. Terazawa T, Iwasa S, Takashima A, et al. Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer[J]. J Cancer Res Clin Oncol, 2013, 139(12): 2111-2116.